Skip to content

Use of Transcranial Direct Current Eletrical Stimulation for treatment of involuntary movements on patients with Schizophrenia

Use of Transcranial Direct Current Stimulation (tDCS) for treatment of Tardive Dyskinesia in schizophrenic patients

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-6zys9x
Enrollment
Unknown
Registered
2018-11-09
Start date
2018-10-23
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tardive Dyskinesia

Interventions

60 individuals with schizophrenia and tardive dyskinesia are going to receive Anodic tDCS stimulation on cerebellum and bilateral primary motor cortex. 5 daily sessions of 20 min, a current of 2mA and
Device

Sponsors

Faculdade de Medicina da Universidade de Brasília - FM/UnB
Lead Sponsor
Faculdade de Medicina da Universidade de Brasília - FM/UnB
Collaborator

Eligibility

Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Individuals diagnosed with schizophrenia (DSV-V) and clinical presentation of Tardive Dyskinesia (Schooler-Kane criteria), both genders, aged between 18 and 65 years, with no changes in drug treatment in the last 4 weeks.

Exclusion criteria

Exclusion criteria: Pregnant, presence of skin disease in the electrode region, patients with relevant psychiatric comorbidity (chemical dependence, suicide risk), neurological diseases (epilepsy, stroke, dementia) and clinical diseases (malignant tumors, infections, cardiac).

Design outcomes

Primary

MeasureTime frame
Reduction of Tardive Dyskinesia, verified by the Abnormal Involuntary Movement Scale (AIMS), based on a score reduction when compared to baseline evaluation (T0).

Secondary

MeasureTime frame
Reduction of symptoms in schizophrenia and global clinical improvement, verified by the The Positive and Negative Syndrome Scale (PANSS) and The Clinical Global Impression (CGI), based on a score reduction when compared to baseline evaluation (T0).

Countries

Brazil

Contacts

Public ContactThiago Correa

Faculdade de Medicina da Universidade de Brasília - FM/UnB

correatx@gmail.com+55 61 98656-2606

Outcome results

None listed

Source: REBEC (via WHO ICTRP)